RT Journal Article
SR Electronic
T1 A Pilot Study of a Ketogenic Diet in Bipolar Disorder: Clinical, Metabolomic and Magnetic Resonance Spectroscopy Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.23.23297391
DO 10.1101/2023.10.23.23297391
A1 Campbell, Iain H
A1 Needham, Nicole
A1 Grossi, Helen
A1 Kamenska, Ivana
A1 Luz, Saturnino
A1 Sheehan, Shane
A1 Thompson, Gerard
A1 Thrippleton, Michael J
A1 Gibbs, Melissa C
A1 Leitao, Joana
A1 Moses, Tessa
A1 Burgess, Karl
A1 Meadowcroft, Ben
A1 Rigby, Benjamin P
A1 Simpson, Sharon A
A1 McIntosh, Emma
A1 Brown, Rachel
A1 Mitchell-Grigorjeva, Maja
A1 Creasy, Frances
A1 Norrie, John
A1 McLellan, Ailsa
A1 Fisher, Cheryl
A1 Campbell, Harry
A1 Smith, Daniel J
YR 2023
UL http://medrxiv.org/content/early/2023/10/23/2023.10.23.23297391.abstract
AB Background Bipolar disorder and epilepsy are treated with anti-seizure medications. Preliminary evidence indicates that a ketogenic diet (a metabolic treatment for epilepsy) may be effective in the treatment of bipolar disorder.Aims To explore the impact of a ketogenic diet on clinical outcomes, and metabolomic and brain magnetic resonance spectroscopy biomarkers.Methods Euthymic individuals with bipolar disorder (N=27) were recruited to a 6-8 week single-arm trial of a modified ketogenic diet and a range of metabolic and clinical outcome measures were assessed.Results There was a positive correlation between daily ketone levels and ecological momentary assessments of mood (p < 0.001) and energy (p < 0.001) and an inverse correlation between ketone levels and impulsivity (p < 0.001) and anxiety (p < 0.001). Mean weight fell by 4.2kg (p < 0.001), mean BMI fell by 5.3% (p < 0.001) and mean systolic blood pressure was reduced by 7.4 mmHg (p < 0.041). Brain Glx (a putative marker of treatment response to anti-seizure medication) decreased by 13.1% in the posterior cingulate cortex (PCC) (p < 0.001) and by 9.2% in the anterior cingulate cortex ACC (p = 0.02). At the dietary cessation period, one third of participants, who reported reduced mood lability, opted to remain on a ketogenic diet.Conclusion The majority of participants had improved cardiometabolic risk parameters and approximately one third experienced improvement in psychiatric symptoms. The study findings are consistent with our a priori hypothesis of ketone bodies acting as an alternative metabolic substrate under conditions of impaired insulin signalling in a subgroup of patients with bipolar disorder.Practitioner Points A ketogenic diet may be effective in improving cardiometabolic risk factors and managing medication-induced weight gain. 95% of participants lost weight with a mean of 4.2kg (p < 0.001) over 8 weeks.Ketone level was correlated to improved daily ecological momentary assessments of mood (p < 0.001) and energy (p < 0.001) and decreased impulsivity (p < 0.001) and anxiety (p < 0.001).Participants who opted out of the dietary cessation period to remain on the diet, and who had reduced Affective Lability Scores, were characterised by more pronounced insulin resistance (HOMA-IR + 27.19%) and higher fasting insulin (+ 19.26%) at baseline.Study Registration Number: ISRCTN61613198Competing Interest StatementDr Iain Campbell has a diagnosis of bipolar disorder and follows a ketogenic diet to manage his symptoms. His current fellowship is funded by the Baszucki Brain Research Fund. Clinical TrialISRCTN61613198Funding StatementThis study was funded by the Baszucki Brain Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received a favourable ethical opinion from the South East Scotland Research Ethics Committee 02.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes